IGF-1 LR3 (Long R3 IGF-1) is a synthetic, extended-acting analog of insulin-like growth factor 1 that is used almost exclusively as an in-vitro cell-culture reagent and as a tool for studying IGF-1 receptor signaling in laboratory models. It differs from native IGF-1 by an arginine-for-glutamate substitution at position 3 and a 13-amino-acid N-terminal extension, changes engineered to sharply lower its binding to IGF-binding proteins (IGFBPs) so that more of the molecule remains available to engage the type I IGF receptor in culture (Francis et al., 1992). This article summarizes its structure, mechanism, and documented research uses. It is intended for laboratory professionals and is for research use only.
What Is IGF-1 LR3?
Native human IGF-1 is a 70-amino-acid single-chain polypeptide. IGF-1 LR3 is an 83-amino-acid variant: the "R3" denotes the substitution of arginine for the native glutamate at residue 3, and "Long" denotes the added 13-residue N-terminal extension peptide (Francis et al., 1992). The compound distributed for research (CAS 143045-27-6) has a molecular weight of roughly 9,117 g/mol, compared with about 7,649 g/mol for native IGF-1.
These modifications were not designed to change what receptor the molecule engages, but to change how freely it can reach that receptor. In native systems, circulating and locally secreted IGFBPs bind IGF-1 with high affinity and restrain its activity. By lowering IGFBP affinity while preserving receptor engagement, IGF-1 LR3 behaves as a more consistently available agonist in experimental systems where binding proteins are present — which is why it became a standard serum-free culture supplement.
How the structural changes alter binding
In the original characterization, the fusion-protein analogs bearing both the position-3 substitution and the N-terminal extension showed markedly reduced affinity for IGFBPs relative to native IGF-1, alongside a comparatively modest reduction in affinity for the type I IGF receptor (Francis et al., 1992). Reported figures in the broader literature place the loss of IGFBP affinity in the range of several hundred-fold or more, while type I IGF receptor affinity is reduced only a few-fold. The net experimental consequence is enhanced biological potency in the presence of binding proteins.
Mechanism of Action
IGF-1 LR3 acts through the same primary target as native IGF-1: the type I IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Ligand engagement triggers receptor autophosphorylation and recruitment of adaptor proteins, activating two principal downstream cascades — the PI3K/Akt axis, associated with survival, protein synthesis, and anti-apoptotic signaling, and the Ras/MAPK (ERK) axis, associated with proliferation and cell-cycle progression. A 2024 review of IGF-1 signaling catalogs these canonical routes along with non-canonical branches involving mTOR, FOXO transcription factors, and receptor cross-talk (Khan et al., 2025).
Because IGF-1 LR3 largely escapes sequestration by IGFBPs, research using it typically observes stronger or more sustained IGF-1R activation at a given nominal concentration than with native IGF-1 in the same culture system. In serum-free HEK293 culture, for example, LONG R3 IGF-1 activated the type I IGF receptor more strongly than either insulin or native IGF-1 at lower concentrations and supported greater cell survival (Voorhamme & Yandell, 2006).
Documented Research Uses
The most established laboratory application of IGF-1 LR3 is as a serum-free cell-culture supplement in bioprocessing and cell-biology research, where it supports proliferation and viability of mammalian cell lines. It is frequently used with Chinese hamster ovary (CHO) and human embryonic kidney (HEK293) lines at concentrations substantially lower than those required for insulin, and it is valued in recombinant-protein workflows for improving growth and productivity of producer cell lines.
Beyond routine culture support, IGF-1 LR3 appears as a comparator or tool compound in mechanistic studies of the IGF axis. In in-vitro-produced bovine embryos, native IGF-1 and Long R3 IGF-1 differentially affected development and the messenger-RNA abundance of IGF-binding proteins and type I IGF receptors, illustrating that the analog and the native ligand are not interchangeable in every system (Prelle et al., 2001). In an animal-model study, Long R3 IGF-1 infusion stimulated organ growth while reducing circulating IGF-1, IGF-2, and IGFBP concentrations in the guinea pig, providing early in-vivo context for how the analog interacts with the endogenous IGF system (Conlon et al., 1995).
Why researchers choose the analog over native IGF-1
The practical appeal in a laboratory setting is reproducibility. Native IGF-1 activity in culture can vary with the IGFBP content of serum, media, or the cells themselves, making dose-response behavior harder to control. An analog that is minimally bound by IGFBPs delivers a more predictable stimulus to the receptor, which is useful both for consistent cell expansion and for cleaner interpretation of signaling experiments.
Handling and Storage
IGF-1 LR3 (99%+) is typically supplied as a lyophilized (freeze-dried) powder. Store the lyophilized material at -20°C, protected from light and moisture. Reconstitute immediately before use following established laboratory protocols; dilute acetic acid or an appropriate buffer is commonly used for IGF-family peptides, after which working dilutions are prepared in culture medium. Aliquot reconstituted stock to avoid repeated freeze-thaw cycles, which can degrade the peptide and reduce activity. As with all research peptides, verify identity and purity against the certificate of analysis before use.
Freshness Note (2026)
As of 2026, IGF-1 LR3 remains a widely used serum-free cell-culture supplement and a standard tool compound in IGF-1R signaling research; no change to its research-only status has occurred. The most current comprehensive overview of the underlying signaling biology is the 2024 Journal of Biological Chemistry review of the IGF-1 signaling landscape (Khan et al., 2025). This article was last updated in July 2026.
Conclusion
IGF-1 LR3 is a structurally modified IGF-1 analog whose defining feature is greatly reduced IGFBP binding, giving it enhanced and more reproducible activity at the type I IGF receptor in laboratory systems. Its best-documented role is as a serum-free culture supplement and as a comparator in mechanistic IGF-axis studies. This product is for research use only and is not intended for human or animal consumption, diagnostic, or therapeutic use.
Frequently Asked Questions
What does "LR3" mean in IGF-1 LR3?
"LR3" is shorthand for "Long R3": "R3" refers to an arginine substitution for glutamate at position 3 of the IGF-1 sequence, and "Long" refers to a 13-amino-acid N-terminal extension peptide. Together these produce an 83-residue analog of the native 70-residue protein (Francis et al., 1992).
How does IGF-1 LR3 differ from native IGF-1 in the lab?
The primary functional difference is dramatically lower affinity for IGF-binding proteins, which leaves more of the molecule free to engage the type I IGF receptor. In serum-free culture this can translate to stronger receptor activation and better cell survival at lower concentrations than native IGF-1 or insulin (Voorhamme & Yandell, 2006).
What is IGF-1 LR3 used for in research?
Its principal documented use is as a serum-free cell-culture supplement supporting proliferation and viability of cell lines such as CHO and HEK293, and as a tool compound in studies of IGF-1 receptor signaling. It is strictly a laboratory reagent and is not intended for human or animal use.
What solvent is used to reconstitute IGF-1 LR3?
IGF-family peptides are commonly reconstituted in dilute acetic acid or a compatible buffer per established laboratory protocols, with subsequent dilution into culture medium. The appropriate solvent depends on the downstream application and compatibility with other reagents.